Explore

Trendline Trendline
Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases
Trendline Trendline
Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback
Trendline Trendline
AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics

AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics

AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback
Trendline Trendline
Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI
Trendline Trendline
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Trendline Trendline
Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab
Trendline Trendline
Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials

Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials

Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
Thryv Therapeutics to Present at Major Healthcare Conferences on SGK1 Inhibitors

Thryv Therapeutics to Present at Major Healthcare Conferences on SGK1 Inhibitors

Thryv Therapeutics to Present at Major Healthcare Conferences on SGK1 Inhibitors